Targeted therapy for metastatic renal cell carcinoma

por Patel, P H, Chaganti, R S K, Motzer, R J
Publicado 2006

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

por Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J
Publicado 2012

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

por Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Publicado 2012

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis...

por Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J
Publicado 2010

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

por Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E
Publicado 2013

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

por Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Uemura, H., Albiges, L., Fujii, Y., Umeyama, Y., Wang, J., Mariani, M., Schmidinger, M.
Publicado 2022

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

por Hutson, T E, Bukowski, R M, Rini, B I, Gore, M E, Larkin, J M, Figlin, R A, Barrios, C H, Escudier, B, Lin, X, Fly, K, Martell, B, Matczak, E, Motzer, R J
Publicado 2014

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris...

por Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.
Publicado 2023

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

por Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Publicado 2014

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

por Staehler, M, Motzer, R J, George, D J, Pandha, H S, Donskov, F, Escudier, B, Pantuck, A J, Patel, A, DeAnnuntis, L, Bhattacharyya, H, Ramaswamy, K, Zanotti, G, Lin, X, Lechuga, M, Serfass, L, Paty, J, Ravaud, A
Publicado 2018

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

por Carlo, M.I., Manley, B., Patil, S., Woo, K.M., Coskey, D.T., Redzematovic, A., Arcila, M., Ladanyi, M., Lee, W., Chen, Y.B., Lee, C.H., Feldman, D.R., Hakimi, A.A., Motzer, R.J., Hsieh, J.J., Voss, M.H.
Publicado 2017

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

por Xu, C-F, Johnson, T, Garcia-Donas, J, Choueiri, T K, Sternberg, C N, Davis, I D, Bing, N, Deen, K C, Xue, Z, McCann, L, Esteban, E, Whittaker, J C, Spraggs, C F, Rodríguez-Antona, C, Pandite, L N, Motzer, R J
Publicado 2015

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

por Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Publicado 2017

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

por Knox, J J, Barrios, C H, Kim, T M, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, S Y, Flaig, T W, Page, R D, Beck, J T, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D, Motzer, R J
Publicado 2018

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

por Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.
Publicado 2021

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ES...

por Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.
Publicado 2021

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

por Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Publicado 2020